 | This article has multiple issues. Please helpimprove it or discuss these issues on thetalk page.(Learn how and when to remove these messages) (Learn how and when to remove this message)
|
| Company type | Subsidiary |
|---|---|
| Nasdaq: CEPH | |
| Industry | Biotechnology,Biopharmaceutical |
| Founded | 1987; 38 years ago (1987) |
| Founder |
|
| Headquarters | Frazer, Pennsylvania[citation needed] |
Key people | J. Kevin Buchi (CEO)[when?][citation needed] |
| Products | alertness drugProvigil, the painkillerActiq, seizure medicationGabitril[1] |
Number of employees | 3,726(December 31, 2010)[citation needed] |
| Parent | Teva Pharmaceutical Industries |
| Website | www |
Cephalon, Inc. was an Americanbiopharmaceuticalcompany co-founded in 1987 by pharmacologistFrank Baldino, Jr.,[1] neuroscientist Michael Lewis, and organic chemist James C. Kauer—all three former scientists with theDuPont Company.[not verified in body] Baldino served as Cephalon's chairman and chief executive officer,[not verified in body] until his death in December 2010.[1] The company's name comes from the adjective "cephalic" meaning "related to the head or brain", as it was established primarily to pursue treatments forneurodegenerative diseases.[not verified in body]
As noted byfundinguniverse.com:
Cephalon initially avoided involving itself in activities that would require maintaining a sales staff, managing clinical trials, and shepherding new drugs through theFood and Drug Administration (FDA) approval process. With no product to sell, Cephalon's only asset was its scientific expertise. That expertise proved sufficient to attract investors, and the company managed to fund its operations through research grants and contracts with larger pharmaceutical firms.[2]
Cephalon was first included in the Fortune 1000 list of U.S. companies based upon annual revenues for 2006.[not verified in body] Sales revenues reached $2.8 billion in 2010,[not verified in body] ranking Cephalon among the leading biopharmaceutical companies in the world at that time.[not verified in body]
On May 2, 2011,Teva Pharmaceutical Industries announced it would acquire Cephalon.[3] The deal was completed on October 11, 2011.[4]
| This section has multiple issues. Please helpimprove it or discuss these issues on thetalk page.(Learn how and when to remove these messages) (Learn how and when to remove this message)
|
The company's early research efforts were focused on the development ofIGF-1, aninsulin-like growth factor, in collaboration withChiron Corporation, toward the development of a treatment foramyotrophic lateral sclerosis (Lou Gehrig's Disease), a candidate that was never approved.[citation needed]
Thereafter, the company developed and commercialized products for the treatment of sleep disorders, pain,[1] addiction and cancer,[citation needed] establishing the "wake franchise"[This quote needs a citation] on the basis of Provigil (modafinil) and later,Nuvigil, theR-enantiomer of modafinil.[citation needed] In addition to conducting research onkinase inhibitors and other small molecules,[citation needed] Cephalon licensed other compounds, purchased other products, and acquired entire companies, in the latter case, including CIMA Labs, Anesta, and Laboratoire Lafon.[citation needed] It was from Lafon that Cephalon obtained the rights tomodafinil, which it marketed under the trade nameProvigil, for the treatment of excessive daytime sleepiness associated withnarcolepsy,sleep apnea, andshift work sleep disorder.[citation needed] Sales of Provigil reached nearly one billion dollars in 2008.[citation needed]
In February 2009, Cephalon acquired the Australian biotechnology firm, Arana Therapeutics, which brought Cephalon its lead biologic candidate, ART621, a candidate for inflammatory diseases,[citation needed] and biologics for the treatment of cancers.[verification needed][citation needed] Then, asinfogrok.com noted in February 2010, "Cephalon... exercised its option to acquire Ception Therapeutics, following receipt of positive data from a clinical study in adults with eosinophilic asthma."[5][better source needed] Commenting on this, Frank Baldino Jr., CEO of Cephalon, said, "The acquisition of Ception is consistent with our strategy to diversify into biologics and provides us with an important phase three asset for further development."[5][better source needed]
At the time of Baldino's death in 2010, the company he had co-founded in 1987 was best known for the alertness drugProvigil, the painkillerActiq, and the seizure disorder medicationGabitril.[1]In 2011, Cephalon agreed to acquire ChemGenex Pharmaceuticals, which would provided Cephalon with marketing rights toOmapro, a therapeutic agent for a drug-resistantleukemia, in theoncology therapeutic area.[6]
 | This sectiondoes notcite anysources. Please helpimprove this section byadding citations to reliable sources. Unsourced material may be challenged andremoved.(February 2020) (Learn how and when to remove this message) |
Longtime chief financial officer J. Kevin Buchi succeeded Baldino as CEO in 2011.[7][8] Members of the board included:[when?] venture capitalist William Egan, former COR Therapeutics CEO Vaughan Kailian, prominent healthcare economist Dr.Gail Wilensky, former SmithKline Beecham executive Dr. Martyn Greenacre, former Harvard physician and Glaxo USA head Dr. Charles Sanders and former Ambassador Kevin Moley.[citation needed]
The company was headquartered west ofPhiladelphia, inFrazer, Pennsylvania, and had research operations in nearbyWest Chester and manufacturing and other operations in suburbanMinneapolis, Minnesota andSalt Lake City, Utah.[citation needed] European operations were based near Paris, France.[citation needed] After the acquisition of Arana,[when?] Research and Development operations continued in Sydney, Australia.[citation needed]
In 1999 Cephalon settled a lawsuit for $17 million in which it had faced claims that Baldino and other company executives had overstated the potential for a drug aimed at treatingamyotrophic lateral sclerosis (Lou Gehrig's disease).[9] In addition, theFederal Trade Commission filed suit against Cephalon,[when?] stating that it had made "illegal deals with generic drug companies to delay generic competition to Provigil", an accusation that Cephalon has reportedly disputed.[1][needs update] In September 2008, Cephalon paid $425 million to the federal government to settle four whistleblower lawsuits and a criminal charge alleging Cephalon had marketed Actiq, Gabitril and Provigil for “off-label” (unapproved) uses.[10][better source needed]
| This sectiondoes notcite anysources. Please helpimprove this section byadding citations to reliable sources. Unsourced material may be challenged andremoved.(February 2020) (Learn how and when to remove this message) |
Select products that Cephalon manufactured and marketed included:[when?][citation needed]
As a small research house, Cephalon initially avoided involving itself in activities that would require maintaining a sales staff, managing clinical trials, and shepherding new drugs through the Food and Drug Administration (FDA) approval process. With no product to sell, Cephalon's only asset was its scientific expertise. That expertise proved sufficient to attract investors, and the company managed to fund its operations through research grants and contracts with larger pharmaceutical firms.
{{cite web}}: CS1 maint: multiple names: authors list (link)